Effect of GH Administration in Poor Responders Undergoing Intracytoplasmic Sperm Injection (ICSI)

• Status: Completed
• Trial end date: 2022-02-13
• Target enrollment: 0
• Participant gender: Female

Summary

Despite the use of various treatment strategies, poor response to ovarian stimulation remains a major clinical challenge with lower chance to obtain sufficient number of oocytes and thus less likely to conceive with high risk of cycle cancellation. The aim of this study is to evaluate the effect of recombinant human GH administration to gonadotropins on clinical and laboratory ICSI outcomes in expected poor responders more and less than 35 years (Poseidon group 4 and 3 respectively).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Alexandria University
• Treatments: Hormones

Criteria

Inclusion Criteria:

1. Infertile women aged 20-45 years.

2. AFC <5.

3. AMH level <1.2 ng/ml.

4. Have two normal ovaries and normal uterine cavity.

Exclusion Criteria:

1. Body mass index (BMI) >30 kg/m2.

2. Follicle Stimulating Hormone (FSH) > 15 IU/L.

3. History of abnormal karyotype in one or both partners.

4. Endocrine, metabolic or autoimmune disorders, such as diabetes, thyroid disorder, and polycystic ovary syndrome (PCOS).

5. Women with a known medical disease (e.g. severe hypertension or hepatic disease).

6. Endometriosis.

7. Previous ovarian surgery.

8. Current or history of malignancies, chemotherapy or radiotherapy.

9. Severe male actor (total motile sperm count <1×106 or normal morphology <1%)